

S 832

EPIC Act of 2025

Congress: 119 (2025–2027, Current)

Chamber: Senate

Policy Area: Health

Introduced: Mar 4, 2025

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Mar 4, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/senate-bill/832>

Sponsor

Name: Sen. Tillis, Thomas [R-NC]

Party: Republican • **State:** NC • **Chamber:** Senate

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blackburn, Marsha [R-TN]	R · TN		Mar 4, 2025
Sen. Budd, Ted [R-NC]	R · NC		Mar 4, 2025
Sen. Daines, Steve [R-MT]	R · MT		Mar 4, 2025
Sen. Lankford, James [R-OK]	R · OK		Mar 4, 2025
Sen. Curtis, John R. [R-UT]	R · UT		Apr 10, 2025
Sen. Banks, Jim [R-IN]	R · IN		Apr 29, 2025
Sen. Marshall, Roger [R-KS]	R · KS		Apr 29, 2025

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 4, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.

